人工泪液联合重组人表皮生长因子滴眼液对白内障囊外摘除术后干眼疗效观察

目的:探讨人工泪液联合重组人表皮生长因子滴眼液治疗白内障囊外摘除术后干眼的临床疗效。方法:选择白内障囊外摘除术后有干眼症状的患者62例62眼,随机分为治疗组和对照组两组,每组31例31眼,治疗组采用人工泪液(泪然)和重组人表皮生长因子(金因舒)滴眼,对照组单用人工泪液。记录患者用药前和用药后2,4wk的干眼症状评分,裂隙灯下观察泪膜破裂时间(BUT)、泪液分泌试验(SchirmerⅠtest,SⅠt)、角膜荧光素染色(FL)情况。结果:治疗前两组干眼症状评分、BUT,SⅠt,FL差异均无统计学意义(P>0.05),用药后2,4wk,治疗组干眼症状评分、BUT,SⅠt,FL与对照组比较,差异均有显著统计学意义(P<0.01)。结论:人工泪液联合重组人表皮生长因子滴眼液治疗白内障囊外摘除术后干眼疗效优于单用人工泪液,效果显著。     

玻璃酸钠联合rhEGF滴眼液治疗白内障摘除术后干眼的疗效

目的:探讨玻璃酸钠滴眼液联合重组人表皮生长因子(rhEGF)滴眼液治疗白内障囊外摘除术后干眼的临床疗效。方法:选择白内障囊外摘除术后有干眼症状的患者42例60眼,随机分为治疗组和对照组两组,每组21例30眼治疗组采用玻璃酸钠滴眼液联合rhEGF滴眼液滴眼,对照组单独使用玻璃酸钠滴眼液。记录患者用药前和用药后2,4wk的干眼症状评分,裂隙灯下观察泪膜破裂时间(BUT)、泪液分泌试验(SchirmerⅠtest,SⅠt)、荧光素染色(FL)情况。结果:治疗前两组干眼症状评分、BUT,SⅠt,FL无显著性差异(P>0.05),用药后2,4wk,治疗组干眼症状评分、BUT,SⅠt,FL与对照组比较,均有显著性差异(P<0.01)。结论:玻璃酸钠滴眼液联合rhEGF滴眼液治疗白内障囊外摘除术后干眼疗效优于单独使用玻璃酸钠滴眼液。     

人工泪液与重组人表皮生长因子衍生物眼液对翼状胬肉术后干眼疗效观察

目的 探讨人工泪液联合重组表皮生长因子衍生物滴眼液治疗翼状胬肉术后干眼的疗效.方法 选择翼状胬肉术后有干眼症状的患者82例(96只眼),随机分为治疗组和对照组两组,每组41例(48只眼),治疗组给予人工泪液(泪然)和重组表皮生长因子衍生物(金因舒)治疗,对照组单用人工泪液,裂隙灯下观察,记录用药前及用药后2周、4周泪膜破裂时间(BUT),泪液分泌实验(schimer-1),角膜荧光素染色(FL)以及干眼症状的改善程度.结果 治疗前,治疗组与对照组Schirmer-1、BUT、FL差异无统计学意义(P>0.05);用药后2周、4周,治疗组schimer-1、BUT、FL以及临床症状的改善与对照组比较,差异有统计学意义(P<0.01).结论 人工泪液联合重组表皮生长因子衍生物滴眼液治疗翼状胬肉术后干眼疗效优于单用人工泪液,效果显著.     

润目增液汤联合人工泪液治疗干眼症的疗效

目的:观察润目增液汤联合人工泪液在干眼症治疗中的临床疗效.方法:采用临床随机对照的研究方法,将临床收集的160例320眼干眼症患者分为两组,分别为治疗组和对照组,每组各80例160眼,治疗组的患者每日口服润目增液汤,频率1剂/d,同时每日予人工泪液滴眼,频率3次/d;对照组的患者每日仅予人工泪液滴眼,频率3次/d,疗程为3mo.记录患者用药前、用药后1、3mo的干眼自觉症状,裂隙灯下观察泪膜破裂时间(BUT)、角膜荧光素染色(FL)、泪液分泌试验(Schirmer Ⅰ test,SⅠt)及疗效情况.结果:治疗前两组干眼患者BUT、FL、SⅠt三项差异均无统计学意义(P>0.05);用药后1、3mo,治疗组干眼BUT、FL、SⅠt及总体疗效相比于对照组,有显著的统计学差异(P<0.05).结论:润目增液汤联合人工泪液用于干眼症治疗的疗效优于单纯使用人工泪液,并且疗效显著.     

聚乙二醇滴眼液联合重组牛碱性成纤维细胞生长因子治疗干眼症

目的:评价聚乙二醇滴眼液联合重组牛碱性成纤维细胞生长因子滴眼液治疗干眼症的疗效。方法:干眼症患者51例102眼,双眼自身对照,随机分为治疗组和对照组。治疗组给予聚乙二醇滴眼液和重组牛碱性成纤维细胞生长因子滴眼液,均4次/d,两种滴眼液之间间隔5～10min。对照组给予聚乙二醇滴眼液滴眼,4次/d,连续用药1mo后复查。观察每组用药前后SchirmerⅠ试验,BUT,角膜荧光素染色和症状改善情况。结果:两组治疗前后BUT,角膜荧光素染色和症状都有显著差异(P<0.05)。两组治疗前后SchirmerⅠ试验结果无显著差异(P>0.05)。治疗后两组BUT,角膜荧光素染色和症状也有显著差异(P<0.05)。结论:聚乙二醇滴眼液联合重组牛碱性成纤维细胞生长因子滴眼液对治疗干眼症有明显的疗效。     

rhEGF滴眼液治疗白内障术后干眼症的效果及对泪膜稳定性的影响

目的：观察重组人表皮生长因子(rhEGF)滴眼液治疗白内障术后干眼症的效果及对泪膜稳定性的影响。

方法：回顾性分析114例158眼白内障术后干眼症患者临床资料,根据干眼症治疗方式分为研究组(rhEGF联合玻璃酸钠组)和对照组(玻璃酸钠组)。治疗4wk后评估疗效、干眼症状(干眼问卷),检查BUT、SⅠt、FL,检测患眼泪液IL-1β、IL-6、TNF-α水平。

结果：研究组总有效率大于对照组(P<0.05)。治疗4wk后,两组BUT、SⅠt均较治疗前升高,且研究组高于对照组(P<0.01); 两组干眼问卷评分及FL、患眼泪液IL-1β、IL-6、TNF-α水平均较治疗前降低,且研究组低于对照组(P<0.05)。

结论：加用rhEGF滴眼液治疗白内障术后干眼症可显著改善患者干眼症状、患眼泪膜稳定性、泪液分泌情况及角膜上皮细胞完整性,减轻炎症反应,疗效显著。     

重组牛bFGF对超声乳化联合IOL植入术后干眼的疗效

目的:评价重组牛碱性成纤维细胞生长因子(basic fibroblast growth factor,bFGF)在白内障超声乳化联合人工晶状体(intraocular lens,IOL)植入术后干眼症状治疗中的应用价值.方法:选取140例140眼白内障超声乳化联合IOL植入术后干眼患者,随机分为对照组和观察组,分别使用聚乙二醇滴眼液和聚乙二醇滴眼液联合重组牛bFGF眼用凝胶治疗.在治疗前和治疗后1 mo进行干眼症状评分和基础泪液分泌试验Ⅰ (Schirmer Ⅰ test,SⅠt)、泪膜破裂时间(tear break-up time,BUT)、角膜荧光素染色检测,统计分析两组疗效差异.结果:治疗前两组患者干眼症状评分和SⅠt、BUT均无统计学差异(P＞0.05).治疗后经配对t检验发现以上三个测量值在两组内比较,差异有统计学意义(P＜0.05),均有明显改善.但治疗后组间比较仅发现观察组的干眼症状评分和BUT明显优于对照组,差异有统计学意义(P＜0.05),观察组的角膜荧光素染色评分下降率显著高于对照组,差异有统计学意义(P＜0.05).结论:针对白内障超声乳化联合IOL植入术后干眼的治疗,联合应用传统人工泪液聚乙二醇和重组牛bFGF较单独应用聚乙二醇可显著改善患者眼部不适,明显延长BUT,有效降低角膜荧光素染色评分,疗效更为理想.     

不同人工泪液对白内障超声乳化吸除术后患者干眼症的临床疗效对比分析

目的:对比分析不同人工泪液对白内障超声乳化吸除术后干眼症的临床疗效.方法:通过对我院2014-03/2017-04行白内障超声乳化吸除术的年龄相关性白内障患者150例150眼的临床资料进行回顾性分析,根据白内障超声乳化吸除术后辅助泪液的不同分为A组(对照组)、B(应用玻璃酸钠滴眼液)、C组(应用卡波姆凝胶滴眼液)3组(各50例50眼).比较并分析三组患者术前、术后1wk,1、3mo BUT、FL评分、SⅠt检查结果及OSDI评分和术前、术后3 mo LogMAR视力情况.结果:三组患者术前、术后1 wk BUT、FL评分、SⅠt检查结果及OSDI评分比较均无差异(P>0.05).术后1mo,B、C组BUT、SⅠt均高于A组,OSDI、FL评分均低于A组(P<0.05),B组与C组BUT、FL评分、SⅠt及OSDI评分比较均无差异(P>0.05).术后3mo,B、C组BUT、SⅠt均高于A组,FL及OSDI评分均低于A组(P<0.05),C组BUT、SⅠt均高于B组,FL及OSDI评分均低于B组(P<0.05).三组患者术后3 mo视力均较术前改善(P<0.05).三组患者术前、术后3 mo视力比较均无差异(P>0.05).结论:白内障超声乳化吸除术辅助不同类型人工泪液治疗年龄相关性白内障,均能在一定程度改善患者干眼症状,其中卡波姆滴眼液或含脂类的人工泪液对于术后干眼症状与体征的改善效果更好,且不会影响视力的恢复.     

bFGF滴眼液与羟糖甘滴眼液对年龄相关性白内障术后泪膜稳定性及干眼症状的影响

目的:比较分析重组牛碱性成纤维细胞生长因子(bFGF)滴眼液与羟糖甘滴眼液对年龄相关性白内障患者术后泪膜稳定性及干眼症状的影响.方法:随机数字法将115例115眼年龄相关性白内障术后干眼患者分为bFGF组、羟糖甘组及空白对照组,空白对照组仅给予常规抗炎治疗,bFGF组、羟糖甘组在空白对照组基础上分别加以bFGF滴眼液、羟糖甘滴眼液治疗,比较各组临床疗效、不良反应、不同时间点干眼症状评分、基础泪液分泌试验(SⅠt)、泪膜破裂时间(BUT)、角膜荧光素染色(CFS)评分变化情况.结果:bFGF组治疗总显效率89.5%比羟糖甘组的70.3%、空白对照组的47.5%高,差异有统计学意义(P<0.05);三组患者术后2、5 wk干眼症状评分、CFS评分、SⅠt、BUT比较差异有统计学意义(P<0.05),且bFGF组术后2、5 wk上述指标均显著优于羟糖甘组及空白对照组,羟糖甘组上述指标均显著优于空白对照组,差异具有统计学意义(P<0.05);三组患者均无明显不良反应发生.结论:年龄相关性白内障术后早期泪膜不稳定,出现干眼症状,bFGF滴眼液、羟糖甘滴眼液干预均能有效恢复患者泪膜稳定性,显著改善干眼症状,其中bFGF滴眼液效果更显著.     

玻璃酸钠滴眼液联合鱼腥草滴眼液治疗干眼症的疗效观察

目的:研究单纯玻璃酸钠滴眼液,及其联合鱼腥草滴眼液治疗干眼症的临床疗效。方法:选取确诊的干眼症患者125例198眼,随机分为单纯玻璃酸钠滴眼液组(A组)63例100眼和玻璃酸钠滴眼液联合鱼腥草滴眼液组(B组)62例98眼。A组用1g/L玻璃酸钠滴眼液治疗;B组交替给予1g/L玻璃酸钠滴眼液和鱼腥草滴眼液治疗。连续治疗2mo后,比较两组治疗前后的临床症状、泪液基础分泌试验(SⅠt)、泪膜破裂时间(BUT)及角膜荧光素染色(FL)程度。结果:两种治疗方法均可明显改善干眼症患者的临床症状、SⅠt,BUT和FL程度;但B组的主观症状、SⅠt,BUT和FL的改善程度明显优于A组。结论:玻璃酸钠滴眼液联合鱼腥草滴眼液可明显改善干眼症患者的临床症状,提高疗效。     

The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study

PURPOSE: To evaluate the effectiveness of the autologous serum eyedrops in the treatment of severe dry eye patients. DESIGN: Prospective randomized case-control study. METHODS: Thirty-seven eyes of twenty severe dry eye patients without punctal occlusion were enrolled in this study. After 2 weeks of washout, they were randomly assigned to two groups. Group A patients used only preservative-free artificial tears, and group S patients used only autologous serum eyedrops. We evaluated the results of Schirmer test, fluorescein and rose bengal staining scores, tear film breakup time (BUT), and subjective symptom scores before and 2 weeks after treatment. RESULTS: Mean BUT and fluorescein and rose bengal staining scores, as well as subjective symptom scores, showed significant improvement in the patients assigned to autologous serum eyedrops compared with subjects assigned to preservative-free artificial tears after 2 weeks of treatment. CONCLUSIONS: Autologous serum eyedrops were found effective in the treatment of severe dry eye disease, as evidenced by improvement of tear stability and ocular surface vital staining scores.     

Comparison of topical dry eye medications for the treatment of keratoconjunctivitis sicca in a botulinum toxin B-induced mouse model

PURPOSE: To compare the effects of topical dry eye medications including anti-inflammatory agents and lubricant eyedrops for the treatment of keratoconjunctivitis sicca (KCS) in a botulinum toxin B (BTX-B)-induced mouse model. METHODS: CBA mice were randomized into 10 groups. The first 5 groups received a transconjunctival injection of saline into the lacrimal gland, and the remaining groups were injected with 0.05 mL of 20 mU BTX-B. Each group received treatment with 0.1% fluorometholone (FML), 0.05% cyclosporine A (CsA), a 50:50 combination of FML and CsA, artificial tears, or saline 3 days after injections. Tear production, corneal staining, and blink rate were compared in each of the 10 groups. RESULTS: Tear production in BTX-B-injected CsA-treated, FML-treated, and combined-treated groups started to return to baseline level within 2 weeks of treatment, whereas those treated with saline or artificial tears still exhibited reduction of lacrimation up to 4 weeks after injection. Topical FML significantly reversed the staining score within 1 week of treatment. The improvement of corneal staining in BTX-B-challenged combined-treated and CsA-treated groups occurred later within 2 weeks after treatment. No significant improvement in corneal staining was observed for the BTX-B-injected mice treated with artificial tears or saline. No significant changes were noted in blink frequency between the control and study groups undergoing the various dry eye therapies. CONCLUSION: The therapeutic effects of dry eye medications in a BTX-B-induced mouse model of KCS are similar to the human response.     

Aggravated dry eye after laser in situ keratomileusis in patients with Sjögren syndrome

PURPOSE: To report 2 patients with Sj?gren syndrome (SS) who had no or mild dry eye symptoms preoperatively but developed severe and refractory dry eye after laser in situ keratomileusis (LASIK). METHODS: Two women with well-controlled early-stage SS developed severe dry eye, punctate epithelial keratopathy, and refractive regression 15 and 2 months after LASIK. Both patients were treated with punctal occlusions, artificial tears, fluorometholone 0.02% eyedrops, autologous serum, and systemic immunosuppressants. RESULTS: Ten months after treatment, both patients exhibited only minor improvements in dry eye symptoms on the basis of changes in Schirmer test results, corneal fluorescein staining, and refractive errors, whereas their tear breakup time and corneal sensation remained unchanged. CONCLUSIONS: Severe and refractory dry eye can develop after LASIK in patients with preexisting well-controlled early-stage SS.     

普拉洛芬滴眼液治疗干眼症眼表炎症的临床评价

目的:观察1g/L普拉洛芬滴眼液控制干眼症患者眼表炎症的疗效和安全性。方法:选择我院2008-04/2008-10门诊诊断为干眼症的患者60眼,随机分成两组,A组为试验组:1g/L普拉洛芬滴眼液及人工泪液联合应用,4次/d点眼,每次1滴。B组为对照组:人工泪液单独应用,4次/d点眼,每次1滴。试验疗程为14d。所有的患者符合入选标准,用药后3,7,14d观察患者的自觉症状、体征、泪膜破裂时间(BUT)、SchirmerⅠ试验、荧光素染色评分等。比较两组的结果,进行统计分析。结果:1g/L普拉洛芬滴眼液及人工泪液联合应用治疗干眼症患者的效果明显优于单纯使用人工泪液治疗组,两组结果有统计学差异。结论:普拉洛芬可以有效控制干眼症患者眼表炎症,是辅助治疗干眼症的有效药物。     

普拉洛芬联合人工泪液在干眼症中的应用

目的:探讨抗炎治疗对于干眼症的临床意义。方法:回顾性分析2008-05/2009-05我院确诊的80例干眼症患者,随机分为人工泪液组(A组)及人工泪液+普拉洛芬组(B组),用药2wk后对比分析调查症状,检测BUT,角膜染色。结果:A组和B组在用药治疗后BUT及角膜病变程度测定两项检查结果比较,差异有统计学意义。B组在改善患者泪膜破裂时间及角膜染色明显优于A组。结论:人工泪液联合应用普拉洛芬,对于伴有眼部刺激症状的干眼症患者具有重要的临床应用价值。     

Corneal epithelial permeability of dry eyes before and after treatment with artificial tears.

PURPOSE: The question of whether artificial tears can lead to objective improvement of ocular surface disease in dry eyes is still unanswered. The aim of the current study is to assess the influence of artificial tears on corneal epithelial permeability of dry eyes. Furthermore, the effect of benzalkonium chloride, used as a preservative of artificial tears, on corneal epithelial permeability is investigated. METHODS: The corneal epithelial permeability of 40 dry eye patients (80 eyes) was measured by computerized objective fluorophotometry before and 6 weeks after treatment with artificial tears containing either polyvinyl pyrrolidone 2% without preservative (20 patients) or polyvinyl pyrrolidone 2% preserved with benzalkonium chloride 0.005% (20 patients). RESULTS: Before treatment, the epithelial permeability of the dry eye patients was found to be 2.7 times that of a control group. After treatment, the epithelial permeability of patients treated with unpreserved polyvinyl pyrrolidone 2% had decreased significantly (-37%; P less than 0.001), whereas patients who had been treated with polyvinyl pyrrolidone 2% preserved with benzalkonium chloride 0.005% showed an increase in epithelial permeability (+21%; P = 0.05%). CONCLUSION: These data suggest that, in dry eyes, treatment with unpreserved artificial tears may lead to an objective improvement in corneal surface disease. However, this effect may be counteracted by preservation of tear substitutes with benzalkonium chloride.     

鱼腥草滴眼液联合人工泪液治疗干眼的临床观察

目的:研究鱼腥草滴眼液联合人工泪液治疗干眼的效果。方法:干眼患者130例244眼随机分为对照组和试验组,以人工泪液和生理盐水滴眼为对照,鱼腥草滴眼液联合和人工泪液治疗为试验组,患者自觉症状、泪膜破裂时间(breaking up time,BUT)、泪液分泌时间(schirmerⅠtest,SⅠt)的变化,并采用结膜印迹细胞学检查(conjunctival impression cytology,CIC)观察眼表结构的改善情况。结果:两组治疗后患者自觉症状均有不同程度改善,对照组BUT较治疗前虽有延长(P<0.05),但SⅠt和CIC评分无明显好转;试验组治疗后BUT,SⅠt及CIC评分较治疗前均有明显改善,且改善程度优于对照组(P<0.01)。结论:鱼腥草滴眼液联合人工泪液治疗干眼依从性好,疗效高。